External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

ISPNO 2024

-
Coming soon
01:05 PM
Duration 10mins Grand Ballroom E - H
Efficacy and safety of entrectinibâ–¼ in children with NTRK or ROS1 fusion-positive (fp) primary central nervous system (CNS) tumors
Aditi Bagchi

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar